Skip to main content
Signal8
Launch Terminal

EXELIXIS, INC. (EXEL)

Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Exelixis, Inc. logo

Exelixis, Inc.

NASDAQ:EXELHealthcare
+4.82%$69.39
AH$69.39+0.00%vs close
Mkt Cap$16.93B
Float240.08M
O/S244.01M
Vol
$ Vol
RVOL
Inst Own-
SI11.4%
Earnings
Dilution
Exelixis, Inc. logoNASDAQ:EXEL$69.39+4.82%
Upcoming Catalysts
Phase Distribution
57 lead-sponsored trials·20 active·18 completed
Phase 132
Phase 1/21
Phase 27
Phase 2/32
Phase 313
Phase 41
Not applicable1
(100 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 4
    Active, not recruiting

    A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer

    Cabozantinib (XL184) 140 mg, Cabozantinib (XL184) 60 mg

    Medullary Thyroid Cancer

    Enrollment
    247
    Start
    Feb 2015
    Primary Completion
    Jul 2020
    Completion
    Jan 2035est.
    NCT01896479
  • Phase 3
    Completed

    Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

    XL184, Placebo

    Thyroid Cancer

    Enrollment
    330
    Start
    Jun 2008
    Primary Completion
    Oct 2011
    Completion
    Sep 2020
    NCT00704730
  • Phase 3
    Terminated

    Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer

    cabozantinib, mitoxantrone

    Prostate Cancer, Castration Resistant Prostate Cancer +2

    Enrollment
    119
    Start
    Mar 2012
    Primary Completion
    Oct 2014
    Completion
    Jan 2015
    NCT01522443
  • Phase 3
    Completed

    Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

    cabozantinib, prednisone

    Prostate Cancer, Castration Resistant Prostate Cancer +2

    Enrollment
    1,028
    Start
    Jul 2012
    Primary Completion
    Sep 2014
    Completion
    Mar 2015
    NCT01605227
  • Phase 3
    Completed

    A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma

    Cabozantinib tablets, Everolimus (Afinitor) tablets

    Renal Cell Carcinoma

    Enrollment
    658
    Start
    Jun 2013
    Primary Completion
    May 2015
    Completion
    Jan 2021
    NCT01865747
  • Phase 3
    Completed

    Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

    Cabozantinib tablets, Placebo tablets

    Hepatocellular Carcinoma

    Enrollment
    707
    Start
    Sep 2013
    Primary Completion
    Oct 2017
    Completion
    Jan 2021
    NCT01908426
  • Phase 3
    Active, not recruiting

    A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

    Cabozantinib, Placebo

    Differentiated Thyroid Cancer

    Enrollment
    187
    Start
    Oct 2018
    Primary Completion
    Aug 2020
    Completion
    Jul 2027est.
    NCT03690388
  • Phase 3
    Active, not recruiting

    Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

    Cabozantinib, Cabozantinib

    Hepatocellular Carcinoma

    Enrollment
    837
    Start
    Jun 2018
    Primary Completion
    Nov 2021
    Completion
    Jul 2026est.
    NCT03755791
  • Phase 3
    Active, not recruiting

    Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

    Cabozantinib, Nivolumab

    Renal Cell Carcinoma

    Enrollment
    855
    Start
    Jun 2019
    Primary Completion
    Jan 2022
    Completion
    Jan 2027est.
    NCT03937219
  • Phase 3
    Active, not recruiting

    Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC

    Cabozantinib, Atezolizumab

    Metastatic Prostate Cancer, Prostate Adenocarcinoma

    Enrollment
    575
    Start
    Oct 2020
    Primary Completion
    Apr 2024
    Completion
    Oct 2026est.
    NCT04446117
  • Phase 3
    Active, not recruiting

    Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

    XL092, Atezolizumab

    Colorectal Cancer

    Enrollment
    901
    Start
    Sep 2022
    Primary Completion
    Jun 2026
    Completion
    Jan 2027est.
    NCT05425940
  • Phase 3
    Active, not recruiting

    Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

    XL092, Nivolumab

    Non-Clear Cell Renal Cell Carcinoma

    Enrollment
    317
    Start
    Jan 2023
    Primary Completion
    Dec 2026est.
    Completion
    Jun 2028est.
    NCT05678673
  • Phase 3
    Enrolling by invitation

    Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

    Cabozantinib, Zanzalintinib

    Cancer, Renal Cell Carcinoma (RCC) +7

    Enrollment
    5,000
    Start
    Jul 2026
    Primary Completion
    May 2030est.
    Completion
    May 2030est.
    NCT07620574
  • Phase 3
    Recruiting

    Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

    Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa

    Colorectal Cancer

    Enrollment
    600
    Start
    Aug 2026est.
    Primary Completion
    Apr 2030est.
    Completion
    Apr 2030est.
    NCT07750158
  • Phase 2/3
    Active, not recruiting

    Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

    Zanzalintinib, Zanzalintinib-matched Placebo

    Head and Neck Squamous Cell Carcinoma

    Enrollment
    600
    Start
    Jun 2024
    Primary Completion
    Aug 2028est.
    Completion
    Mar 2029est.
    NCT06082167
  • Phase 2/3
    Recruiting

    Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

    Zanzalintinib, Everolimus

    Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)

    Enrollment
    440
    Start
    Jul 2025
    Primary Completion
    Jun 2029est.
    Completion
    Jun 2029est.
    NCT06943755
  • Phase 2
    Completed

    A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib

    XL820, XL820

    Gastrointestinal Stromal Tumors, Gastrointestinal Neoplasms

    Enrollment
    16
    Start
    Dec 2007
    Primary Completion
    May 2009
    Completion
    May 2009
    NCT00570635
  • Phase 2
    Completed

    Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme

    XL184

    Glioblastoma Multiforme

    Enrollment
    222
    Start
    May 2008
    Primary Completion
    Jun 2012
    Completion
    Dec 2012
    NCT00704288
  • Phase 2
    Completed

    Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

    Cabozantinib, Placebo

    Solid Tumors, Cancer

    Enrollment
    730
    Start
    Sep 2009
    Primary Completion
    May 2013
    Completion
    Jun 2014
    NCT00940225
  • Phase 2
    Terminated

    Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

    Cabozantinib

    Astrocytic Tumors

    Enrollment
    19
    Start
    Apr 2010
    Primary Completion
    May 2011
    Completion
    Oct 2013
    NCT01068782
  • Phase 2
    Terminated

    Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC

    cabozantinib, abiraterone

    Prostate Cancer, Castration Resistant Prostate Cancer +1

    Enrollment
    54
    Start
    Feb 2014
    Primary Completion
    Nov 2014
    Completion
    Nov 2014
    NCT01995058
  • Phase 2
    Recruiting

    A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma

    Zanzalintinib

    Meningioma

    Enrollment
    100
    Start
    May 2026
    Primary Completion
    Feb 2028est.
    Completion
    Sep 2029est.
    NCT07428616
  • Phase 2
    Not yet recruiting

    Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)

    Carboplatin, Paclitaxel

    Squamous Non-Small Cell Lung Cancer (NSCLC)

    Enrollment
    60
    Start
    Dec 2026est.
    Primary Completion
    Jun 2028est.
    Completion
    Jun 2030est.
    NCT07845786
  • Phase 1/2
    Completed

    A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)

    XL184, erlotinib

    Carcinoma, Non-Small-Cell Lung

    Enrollment
    92
    Start
    Feb 2008
    Primary Completion
    Aug 2012
    Completion
    Aug 2012
    NCT00596648
  • Phase 1
    Completed

    Study of XL820 in Adults With Solid Tumors

    XL820

    Cancer

    Enrollment
    -
    Start
    Aug 2005
    Primary Completion
    -
    Completion
    -
    NCT00129571

1-25 of 57

Search ClinicalTrials.gov for “Exelixis”